{"id":"W1911252495","doi":"","title":"A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.","year":2001,"lang":"en","type":"article","venue":"PubMed","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":192,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Mitoxantrone; Prostate cancer; Medicine; Chemotherapy; Internal medicine; Cancer; Urology; Phases of clinical research; Neutropenia; Gastroenterology; Oncology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001331706,0.002066853,0.002867915,0.0008748652,0.0004321426,0.0009637369,0.001441109,0.001601678,0.003185945],"category_scores_gemma":[0.0009755048,0.0007954304,0.001350568,0.0006713191,0.001743169,0.0009622877,0.0005107158,0.003007018,0.0006538202],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001074257,"about_ca_system_score_gemma":0.001609901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001228827,"about_ca_topic_score_gemma":0.002709768,"domain_scores_codex":[0.9992987,0.0003465358,0.00002785982,0.0001305204,0.00006781928,0.0001285829],"domain_scores_gemma":[0.9990741,0.0001530903,0.0001759532,0.0000940551,0.00004880399,0.0004540236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6547022,0.1416771,0.005599227,0.0009179404,0.002089198,0.0004082958,0.0004561228,0.00501917,0.08885991,0.0003686059,0.001912213,0.09798992],"study_design_scores_gemma":[0.2497219,0.7398326,0.003580753,0.0000208799,0.0003154549,0.0002077585,0.00004375234,0.0006788285,0.004384222,0.00007520351,0.001118822,0.00001975548],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931985,0.001935219,0.0005755093,0.0002457125,0.0001204791,0.002380675,0.0003245389,0.00007976752,0.001139638],"genre_scores_gemma":[0.9902266,0.001818379,0.002383928,0.0003821923,0.0001878453,0.002664452,0.0007794553,0.00002341292,0.001533767],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003185945,"threshold_uncertainty_score":0.01065809,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03681151704988009,"score_gpt":0.3088887734766909,"score_spread":0.2720772564268108,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}